Podcast
Breast Cancer Update
Hosted by Dr. Neil Love · EN
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
39episodes
Episodes
Newest firstAll episodes
Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway
3d ago01:58:16Tap to summarizeFeaturing perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:Introduction (0:00)Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)CME information and select publications
Transcribe →HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy
1w ago00:46:28Tap to summarizeFeaturing an interview with Prof Dr Sibylle Loibl, including the following topics:Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)CME information and select publications
Transcribe →Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
2w ago00:58:12Tap to summarizeFeaturing perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:Introduction: ODAC — April 30, 2026 (00:00)Adjuvant CDK4/6 Inhibitors (13:03)Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)Premenopausal Patients (30:52)Duration of Adjuvant Endocrine Treatment (38:44)Genomic Predictors of Chemotherapy Benefit (47:19)Neoadjuvant Treatment (55:13)CME information and select publications
Transcribe →For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
3w ago01:28:54Tap to summarizeFeaturing perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:Introduction (0:00)Overview of Antibody-Drug Conjugates (ADCs) (2:07)Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)Currently Available ADCs for Gynecologic Cancer Management (26:37)Currently Available ADCs for Lung Cancer Management (44:07)Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)NCPD information and select publications
Transcribe →Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
3w ago02:00:00Tap to summarizeFeaturing perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:Introduction (00:00)Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)CME information and select publications
Transcribe →HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
4w ago01:39:19Tap to summarizeFeaturing perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics:Introduction (0:00)Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)CME information and select publications
Transcribe →Metastatic Triple-Negative Breast Cancer — What Clinicians Want to Know
Jun 2600:53:43Tap to summarizeFeaturing perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics: Introduction: Where We Are; Where We’re Heading (0:00)First-Line Treatment of BRCA Wild-Type Disease (9:14)First-Line Treatment of BRCA-Mutant Disease (38:48)Novel Approaches (47:49)CME information and select publications
Transcribe →HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Jun 2300:52:17Tap to summarizeFeaturing perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics:Introduction (0:00)Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51)CME information and select publications
Transcribe →Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper
Jun 2200:23:46Tap to summarizeFeaturing an interview with Prof Bernd Kasper, including the following topics:Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00)Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04)Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58)Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapular region (17:19)CME information and select publications
Transcribe →Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit
Jun 2000:49:19Tap to summarizeFeaturing perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics:Introduction (0:00)Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08)Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20)CME information and select publications
Transcribe →